Skip to main content
HR 4369 117th Congress House Health Advanced technology and technological innovations Congressional oversight Department of Health and Human Services Drug safety, medical device, and laboratory regulation Food and Drug Administration (FDA) Government information and archives Health programs administration and funding Health technology, devices, supplies Higher education Manufacturing Prescription drugs Product development and innovation Research administration and funding Research and development

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

Introduced: July 6, 2021 Introduced by: Pallone, Frank Democratic · New Jersey See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 19 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 20, 2021
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Oct 19, 2021
DEBATE - The House proceeded with forty minutes of debate on H.R. 4369.
Oct 19, 2021
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 368 - 56 (Roll no. 318).(text: CR H5645-5647)
Oct 19, 2021
Considered as unfinished business. (consideration: CR H5662-5663)
Oct 19, 2021
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Oct 19, 2021
Considered under suspension of the rules. (consideration: CR H5645-5647)
Oct 19, 2021
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Oct 19, 2021
Placed on the Union Calendar, Calendar No. 111.
Oct 19, 2021
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-151.
Oct 19, 2021
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 368 - 56 (Roll no. 318). (text: CR H5645-5647)
Oct 19, 2021
The title of the measure was amended. Agreed to without objection.
Oct 19, 2021
Motion to reconsider laid on the table Agreed to without objection.
Jul 21, 2021
Committee Consideration and Mark-up Session Held.
Jul 21, 2021
Ordered to be Reported (Amended) by Voice Vote.
Jul 15, 2021
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Jul 15, 2021
Subcommittee Consideration and Mark-up Session Held.
Jul 7, 2021
Referred to the Subcommittee on Health.
Jul 6, 2021
Introduced in House
Jul 6, 2021
Referred to the House Committee on Energy and Commerce.
 Votes taken on this bill 1
DateChamberWhat was voted onResultYes–No
Oct 19, 2021 House · vote #318 On Motion to Suspend the Rules and Pass, as Amended Passed 368–56 See who voted →
 Plain-English summary Congressional Research Service

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on advanced and continuous pharmaceutical manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

What's happening now October 20, 2021

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Committees of jurisdiction 3
 Cosponsors 1
All 1 Republican 1